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ARTICLE
The utility of serology for elimination surveillance
of trachoma
Amy Pinsent1,2, Anthony W. Solomon3,4, Robin L. Bailey4, Rhiannon Bid4, Anaseini Cama5,6, Deborah Dean7,
Brook Goodhew8, Sarah E. Gwyn8, Kelvin R. Jack9, Ram Prasad Kandel10, Mike Kama11, Patrick Massae12,
Colin Macleod4,13, David C.W. Mabey4, Stephanie Migchelsen4, Andreas Müller14, Frank Sandi12,15,
Oliver Sokana9, Raebwebwe Taoaba16, Rabebe Tekeraoi16, Diana L. Martin8 & Michael.T. White17
Robust surveillance methods are needed for trachoma control and recrudescence monitoring,
but existing methods have limitations. Here, we analyse data from nine trachoma-endemic
populations and provide operational thresholds for interpretation of serological data in
low-transmission and post-elimination settings. Analyses with sero-catalytic and antibody
acquisition models provide insights into transmission history within each population. To
accurately estimate sero-conversion rates (SCR) for trachoma in populations with high-
seroprevalence in adults, the model accounts for secondary exposure to Chlamydia tracho-
matis due to urogenital infection. We estimate the population half-life of sero-reversion for
anti-Pgp3 antibodies to be 26 (95% credible interval (CrI): 21–34) years. We show SCRs
below 0.015 (95% conﬁdence interval (CI): 0.0–0.049) per year correspond to a prevalence
of trachomatous inﬂammation—follicular below 5%, the current threshold for elimination of
active trachoma as a public health problem. As global trachoma prevalence declines, we may
need cross-sectional serological survey data to inform programmatic decisions.
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Trachoma is a neglected tropical disease (NTD) caused byrepeated infection with the bacterial pathogen Chlamydiatrachomatis (Ct)1 and is targeted for elimination as a public
health problem by 2020. In 2016, an estimated 190.2 million
people were at risk of trachomatous blindness in 41 countries2.
There has been substantial progress towards achieving elimina-
tion of trachoma as a public health problem2, with many coun-
tries accelerating towards the active trachoma target of a
prevalence of trachomatous inﬂammation—follicular (TF) <5% in
all previously-endemic districts.
Following elimination of trachoma as a public health problem,
robust surveillance for disease recrudescence will be needed.
Currently, programmatic decisions for trachoma control—speci-
ﬁcally, for the number of rounds of azithromycin mass drug
administration (MDA) rounds required before re-estimation of
prevalence, and for MDA discontinuation—are made based on
TF prevalence in children aged 1–9 years. Once a TF prevalence
of <5% has been achieved, a pre-validation surveillance survey is
required to assess whether re-emergence is occurring or not; if TF
prevalence is found to be ≥5%, re-initiation of MDA would be
indicated. At low levels of TF prevalence, there is no clear asso-
ciation between the prevalence of TF and ocular Ct infection3,
making the interpretation of data difﬁcult, and suggesting that
different diagnostics may be required at particular phases of
programmatic monitoring and evaluation. Furthermore when
active trachoma prevalence falls, it becomes difﬁcult to adequately
train graders and prove they are proﬁcient at identifying TF4.
There is therefore a clear need for surveillance methods that
accurately monitor low levels of transmission, and serology is
potentially one such method.
Identiﬁcation of optimal approaches for surveillance following the
cessation of interventions remains an on-going challenge for
numerous infectious diseases5,6. Serological assays measuring anti-
body responses resulting from a single or cumulative exposure to a
pathogen have been used to measure and assess changes in trans-
mission intensity7, including examining the impact of interventions
on transmission8. Such testing can potentially be integrated into
existing surveillance mechanisms. Modelling sero-epidemiological
data to understand patterns of transmission is well-established in
inﬂuenza and malaria epidemiology6,9, and is increasingly performed
for other infectious diseases, including onchocerciasis10, Chagas dis-
ease11, and lymphatic ﬁlariasis12. Given the insights provided through
the analysis of serological data for other pathogens, serology has been
suggested as a complementary or alternative surveillance tool to the
use of clinical signs in trachoma programmes. Antibodies against two
Ct-derived antigens (Pgp3 and CT694) are detectable in a very high
proportion of people with ocular Ct infection7. However, Pgp3
and CT694 are shared by Ct serovars associated with urogenital
infection, complicating our understanding of patterns of ocular Ct
transmission13,14. If an accurate understanding of ocular Ct trans-
mission is to be inferred from analysis of population-level serological
data, a second potential source of exposure to Ct antigens via uro-
genital infection must be considered.
To evaluate the utility of serology as a tool for early detection of
recrudescence, evidence must be analysed from a range of epi-
demiological settings15. Particular requirements for results from
sero-surveillance to be informative include an adequate under-
standing of the population-level sero-reversion rate (SRR) and
antibody dynamics, so changes in transmission can be monitored
post-validation.
The collection and analysis of Ct serology data is an ongoing
and active area of trachoma research. A previous modelling
analysis of serological data from Rombo, Tanzania suggested that
a step-wise drop in transmission occurred ~15 years prior to the
survey date16. Equally, a study analysing data from The Gambia
also suggested that a step-wise drop in transmission occurred
19–23 years prior to sampling14. However, in analyses to date,
no consideration has been given to age-dependent exposure to
urogenital Ct when estimating the sero-conversion rate (SCR).
Furthermore, previous studies have either assumed that sero-
reversion following conversion does not occur at all16 or that it
takes on average at least 65 years14 and estimates of this para-
meter have been limited to data from one cross-sectional survey.
Therefore, more research is required in order to estimate the SRR
from multiple cross-sectional surveys, and to estimate the SCR
whilst accounting for the potential exposure to urogenital Ct in
settings where this may be a problem.
In this study, we explore age-speciﬁc variation in antibody
responses to Ct. We demonstrate how sero-catalytic and antibody
acquisition models provide insight into current and historical pat-
terns of trachoma transmission. We quantify the relationship
between the estimated Ct sero-prevalence and TF prevalence to help
guide the framing of operational thresholds for sero-surveillance data.
Results
Overview of the analysis. We performed analysis on 9 data sets
from 6 different geographic regions and analysed the data using
two different statistical models: sero-catalytic models and anti-
body acquisition models. We evaluated age-dependent changes in
anti-Pgp3 and anti-CT694 antibody prevalence to infer historical
patterns of transmission within each setting. For each of the
different model types (sero-prevalence and antibody acquisition)
three distinct transmission scenarios were considered: scenario 1
assumed a constant rate of transmission; scenario 2 assumed a
sharp drop in transmission tc years ago; and scenario 3 assumed
a linear decline in transmission8,17. We ﬁtted up to 10 different
transmission scenarios to each dataset. To understand the rela-
tionship between different measures of transmission intensity
(SCR and TF prevalence) we ﬁtted a linear model to the rela-
tionship between the SCR for trachoma (λT) (for Pgp3) and TF
prevalence for each study site. Full details on the methodology are
provided in the Methods section and Supplementary Methods.
Correlation between antibody responses against two Ct anti-
gens and age. We observed a strong positive correlation between
antibody responses against the two antigens in Nepal, both pre-
and post-MDA, and in Rombo (correlation coefﬁcients 0.80,
0.85, 0.83 for the three data sets, respectively). For all study sites
there was a strong positive correlation between age and antibody
response (measured in MFI-BG or OD), with older individuals
having higher antibody responses than younger individuals
(Supplementary Figure 1).
Sero-catalytic modelling. In Fig. 1 we present the sero-pre-
valence, TF prevalence and the ﬁt of the most suitable sero-
catalytic model scenario for each dataset. Parameter estimates for
the best-performing model for each of the nine data sets are
presented in Table 1. Full sets of parameter estimates for every
model ﬁtted are presented in Supplementary Tables 3–13 and
Supplementary Figures 3-13.
Sero-catalytic models were ﬁtted to the anti-Pgp3 and anti-
CT694 antibody data from the pre- and post-MDA cross-sections
from Nepal simultaneously. The data were best described by
scenario 2v1: a step-wise decrease in transmission (Fig. 1a,
Supplementary Table 3). Antibody responses to both antigens had
similar estimates of λT: 0.143 (95% credible interval (CrI):
0.107–0.215) per year and 0.142 (95% CrI: 0.103–0.207) per year
for Pgp3 and CT694, respectively (Table 2). Antibody responses
against Pgp3 and CT694 had differing longevity, with the half-life
for sero-reversion estimated as 26 (95% CrI: 21–34) years, and 40
(95% CrI: 33–53) years for Pgp3 and CT694, respectively. After
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MDA, transmission was reduced by 5 and 10% of pre-intervention
levels, with this difference being consistent when using antibody
responses to either antigen. The estimated time of change in
transmission (tc) was 13–17 years prior to the second cross-section
using antibody responses to Pgp3, and 14–18 years prior to the
second cross-section using antibody responses to CT694.
Data from Lower and Upper River regions (LRR and URR) of
The Gambia, from Rennell & Bellona and Temotu provinces in the
Solomon Islands, and from Rombo (both antigens) were all ﬁtted
separately. For all populations, scenario 3v4 was most appropriate (a
linear reduction in transmission) with ﬁxed ρ, also accounting for
exposure to urogenital Ct at sexual debut (Fig. 1c–h). This pattern
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Fig. 1 Fits of the best-performing sero-catalytic models to age-speciﬁc sero-prevalence data. The titles within each panel indicate the study site, antigen-
speciﬁc antibody responses measured and the best ﬁtting transmission scenario for that dataset. Black squares indicate the proportion sero-positive in
each age-group and green triangles indicate the age-group speciﬁc TF prevalence. Black and green data points on the Nepal plots indicate pre and post-
MDA, respectively. Error bars on the squares and triangles indicate the 95% binomial conﬁdence intervals. Solid black lines running through the sero-
prevalence data were generated with the median parameter estimates from each model ﬁt. The shaded grey region represents the 95% credible intervals of
the model predictions. Uncertainty was generated by drawing 500 independent samples from the posterior distribution
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corresponds to declining trachoma transmission over time (akin to
a secular decline) without a sharp reduction. Sero-prevalence curves
observed in Rombo and The Gambia were very similar to one
another, suggesting the locations are epidemiologically similar. In
both settings scenario 2v1 was either statistically comparable or
better performing based on the Deviance Information Criterion
(DIC). Although model estimates are consistent with declining
transmission in these regions, the exact magnitude of this reduction
was not identiﬁable because of the simultaneous age-dependent
exposure to urogenital infection (Table 2).
Data sets from Kiribati and Fiji included only individuals <16
years old. In Kiribati, we saw increasing sero-prevalence by age
(Fig. 1i). No increase in sero-positivity with age was observed
in Fiji (Fig. 1j, k). Scenario 3v3 was most suitable for Kiribati
(Fig. 1i, Supplementary Table 11). λT was 0.32 (95% CrI:
0.17–0.52) per year and γ was 0.063 (95% CrI: 0.034–0.204)
(Table 2). In Fiji all scenarios provided comparably poor ﬁts to
the data and there was no epidemiological evidence to support
the scenario that had the highest statistical support (Scenario 2v2
for both ethnic populations, Supplementary Table 12 & 13).
Therefore scenario 1v2 (assuming a constant level of transmission
with a ﬁxed ρ) was selected as the most parsimonious model
(Table 2 and Supplementary Table 12 & 13). Low rates of λT
were estimated: 0.053 (95% CrI: 0.044–0.063) per year and 0.006
(95% CrI: 0.001–0.014) per year for the iTaukei and Indo-Fijian
populations respectively (Table 2).
Antibody acquisition modelling. Fitting the antibody acquisition
(AA) model to the data from Nepal, greater statistical support
was provided for scenario 2v1 (Fig. 2, Supplementary Tables 14
& 15). The estimated rate of antibody acquisition (αT) was 0.362
(95% CrI: 0.327–0.403) per year for Pgp3, and 0.373 (95% CrI:
0.329–0.437) per year for CT694 (Supplementary Tables 13 & 14).
The estimated antibody level half-life (accounting for both the
decay of circulating IgG and the generation of new IgG) was 7.3
(95% CrI: 6.5–8.2) years and 5.5 (95% CrI: 4.7–6.3) years for
Pgp3 and CT694, respectively, a shorter duration than the half-
life of sero-positivity. Model ﬁts to data sets with a single cross-
section are provided in the Supplementary Tables 14–24 and
Supplementary Figures 14–22, discussion of these results are
provided in the Supplementary discussion.
Relationship between λT and TF prevalence. The association
between TF prevalence (in 1–9 year olds) and the SCR was captured
using a linear model (Fig. 3a). The relationship provides a bridge
between estimates of transmission intensity based on either TF
prevalence data or serological data. The predicted λT when TF
prevalence was <5% was 0.015 (95% CI: 0.0–0.051) per year
(Fig. 3a). The expected proportion of sero-positive individuals at
a TF prevalence of <5% was 6.2% (95% CI: 0.0–19.9%) (Fig. 3b).
Assessing sub-critical transmission in serological data. Fig-
ure 4a presents a simulated dataset from a population aged 1–60
years, 10 years after elimination of trachoma as a public health
problem. Older individuals have higher antibody positivity, as a
result of either long-lived response to ocular Ct or exposure to
urogenital Ct after trachoma’s elimination as a public health pro-
blem, with much lower or no sero-positivity in children. Assessing
individuals aged 1–9 years born after trachoma has been eliminated
Table 1 Deﬁnitions of each transmission scenario and the parameters estimated from the data
Model name Transmission assumption λT λUG ρ tc γ
Scenario 1v1 Constant Yes No Yes No No
Scenario 1v2 Constant Yes No No No No
Scenario 2v1 Fixed change point Yes No Yes Yes Yes
Scenario 2v2 Fixed change point Yes No No Yes Yes
Scenario 2v3 Fixed change point Yes Yes Yes Yes Yes
Scenario 2v4 Fixed change point Yes Yes No Yes Yes
Scenario 3v1 Linear decline Yes No Yes No Yes
Scenario 3v2 Linear decline Yes Yes Yes No Yes
Scenario 3v3 Linear decline Yes No No No Yes
Scenario 3v4 Linear decline Yes Yes No No Yes
For each scenario we indicate with a yes or a no as to whether or not a given parameter was estimated from the data for that scenario. The parameters listed are deﬁned as follows: λT (Rate of sero-
conversion due to exposure to trachoma), λUG (Rate of sero-conversion due to exposure to urogenital infection), ρ (Rate of sero-reversion), tc(Fixed time point at which transmission intensity changed), γ
(Proportional decline in transmission at tc or over time). Note that the interpretation of γ for scenario 2 and 3 are different. For scenario 2, it is the ratio between average transmission rates of two time
intervals. For scenario 3, it is the ratio between two end points of the whole study period
Table 2 Estimated parameters for the best ﬁtting sero-catalytic models to each of the 9 data sets
Study site Model λT γ p tc λUG DIC
Nepal (Pgp3) Scenario 2v1 0.143 (0.107–0.215) 0.053 (0.031–0.084) 0.026 (0.020–0.032) 16.06 (13.57–17.69) — 1325.11
Nepal (CT694) Scenario 2v1 0.142 (0.103–0.207) 0.062 (0.037–0.097) 0.017 (0.013–0.021) 16.84 (14.93–18.65) — 1252.95
Gambia LRR Scenario 3v4 0.021 (0.013–0.03) 0.677 (0.268–0.984) — — 0.067 (0.049–0.090) 866.64
Gambia URR Scenario 3v4 0.023 (0.010–0.184) 0.591 (0.112–0.893) — — 0.063 (0.015–0.595) 678.64
Rombo (Pgp3) Scenario 3v4 0.022 (0.009–0.041) 0.177 (0.019–0.881) — — 0.092 (0.061–0.127) 379.74
Rombo (CT694) Scenario 3v4 0.008 (0.004–0.016) 0.172 (0.002–0.567) — — 0.048 (0.031–0.062) 326.74
Temotu Scenario 3v4 0.045 (0.028–0.075) 0.585 (0.218–0.986) — — 0.021 (0.001–0.041) 1440.54
Rennell & Bellona Scenario 3v4 0.092 (0.061–0.170) 0.746 (0.319–0.995) — — 0.255 (0.085–0.499) 247.34
Kiribati Scenario 3v3 1.080 (0.345–1.737) 0.063 (0.034–0.204) — — — 453.45
iTaukei Scenario 1v2 0.053 (0.044–0.063) — — — — 554.99
Indo-Fijian Scenario 1v2 0.006 (0.001–0.014) — — — — 23.30
We present the median posterior estimates, the 2.5% and 97.5% credible intervals (CrI) for each parameter for each model and the Deviance information criteria (DIC) for each model (note that DIC
values should not be compared between different model ﬁts to different data sets). λT - rate of sero-conversion due to exposure to trachoma, λUG - rate of sero-conversion due to exposure to urogenital
infection, ρ - rate of sero-reversion, tc - ﬁxed time point at which transmission intensity changed, γ - proportional decline in transmission at tc or over time. Lower River Region (LRR), Upper River Region
(URR)
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as a public health problem (Fig. 4b), one of three scenarios may
be observed. The ﬁrst scenario shows no young individuals
testing sero-positive (black line). The second scenario shows a
slight increase in sero-positivity with age (pink line) due to on-
going low-level Ct transmission despite TF being below the 5%
threshold. The third scenario shows constant, non-zero sero-pre-
valence across the 1–9 year old age bracket (blue line), reﬂecting
either low-level but not constant transmission or cross-reactivity
resulting in a non-speciﬁc measurement of antibody response.
Sampling for elimination as a public health problem. Figure 4c
presents the number of samples in 1–9 year olds required to
provide statistically robust evidence that sero-prevalence was
below a given threshold, assuming a type 1 error of 5%. In a
population with no Ct-sero-positive individuals, at least 368 sero-
negative samples are needed to provide statistically signiﬁcant
evidence that sero-prevalence was <1%, assuming random sam-
pling of the underlying population. Demonstrating sero-
prevalence below the lower threshold of 0.1% would require an
impractical 3766 negative samples. In contrast, demonstrating
evidence of sero-prevalence <7% would require only 51 sero-
negative samples. However, these estimates of sample numbers
are contingent on all samples testing sero-negative. For example,
although obtaining 0/51 sero-positive samples provides statistical
support for sero-prevalence <7%, just one sero-positive sample
would give an estimated sero-prevalence of 1/51= 2%. This is
<7%, but not signiﬁcantly lower than 7%. Increasing sample
numbers allows for some samples to test positive, with estimated
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Fig. 2 Fits of the best-performing antibody acquisition model for data from Nepal. Black points indicate the pre-MDA data and green indicate the post-
MDA data. Error bars on the squares and triangles indicate the 95% binomial conﬁdence intervals. Solid black lines running through the sero-prevalence
data were generated with the median parameter estimates from each model ﬁt. The shaded grey region represents 95% credible intervals of the model
predictions. Uncertainty was generated by drawing 500 independent samples from the posterior distribution
0.20
0.20 0.25 0.30
TF prevalence TF prevalence
a b
0.15
0.15
0.10
0.10
0.05
0.05
0.00 0.0
0.2
0.4
0.6
0.8
1.0
SCR ∼ TF + TF∧2 Prop sero–positive: 1–9 years
0.00 0.20 0.25 0.300.150.100.050.00
Se
ro
-c
on
ve
rs
io
n 
ra
te
Pr
op
or
tio
n 
se
ro
-p
os
itiv
e
Fig. 3 The estimated relationship between the sero-conversion rate (SCR) and TF prevalence and the predicted proportion of people sero-positive. a Black
dots indicate the median estimated SCR for each dataset and the TF prevalence from each of the 9 study sites. The solid black line is the mean predicted
relationship between the SCR and TF prevalence, obtained by ﬁtting a linear model to the data. The 95% conﬁdence intervals about the mean relationship
are indicated as grey dashed lines. b The predicted mean proportion of people sero-positive for a given level of TF prevalence is shown with a solid black
line, the 95% conﬁdence intervals about this mean are indicated with dashed grey lines. For the elimination as a public health problem threshold of TF <5%,
we would expect 6.2% (95% CI: 0.0–19.9%) to test sero-positive
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(pink line), or no sero-positive individuals in the community at all reﬂecting complete elimination (black line). c Estimate of the number of samples required
from children aged 1–9 years to provide statistical evidence that sero-prevalence is below thresholds of: 0.1%, 1%, 4.9%, 7 and 15%. If the true sero-
prevalence= 0% such that all samples test negative, the number of samples required is shown where the curves intersect the y-axis. In the situation where
there is some low level of transmission, the number of samples increases substantially. For example, if the true sero-prevalence= 0.5%, then 368 samples
are needed to provide evidence of sero-positivity <1%
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sero-prevalence still signiﬁcantly lower than 7%. With 100 sam-
ples, we can have up to 1 sero-positive sample for sero-prevalence
estimates signiﬁcantly lower than 7%. For 200 samples, the
number of allowable sero-positive samples rises to 6.
Discussion
Serological surveillance for trachoma is being considered to help
programmes undertake post-validation surveillance. Prior ana-
lyses of the potential utility of serology have used only single-
study-site data, with few studies taking a quantitative modelling
approach14,18. In all settings evaluated, our modelling suggested
transmission of trachoma had declined over time, either through
a step-change in transmission, or more linearly. We estimated
SRR half-life to be 26 (95% CrI: 21–34) years and 40 (95% CrI:
33–53) years, with an estimated half-life of the antibody response
to be 7.3 (95% CrI: 6.5–8.2) years and 5.5 (95% CrI: 4.7–6.3)
years, for Pgp3 and CT694, respectively—the ﬁrst estimates
published for these parameters. Our results suggested that SCRs
below 0.015 per year correspond to TF <5%, and that the mean
sero-prevalence for 1–9 year olds when TF <5% was <7%. Whilst
more data are needed to reduce the uncertainty in the relation-
ship between sero-prevalence and TF prevalence, we present an
initial operational threshold for interpreting serological data in
trachoma programmes.
In most settings, the sero-prevalence of anti-Ct antibodies
increased with age. A typical ocular Ct infection commonly lasts
only a few weeks or months, which may or may not be sufﬁcient to
develop long-lived plasma cells that secrete antibodies for many
years, even in the absence of subsequent infection that would
provide boosting of the response. Though it is impossible to rule out
bacterial persistence in tissues, it is more likely that the increase in
sero-prevalence with increasing age is due to repeated infection with
ocular Ct leading to the induction of plasma cells19–21. Therefore,
we believe that the measured response reﬂects cumulative exposure
to the pathogen and immunological memory.
We have presented a novel approach to account for secondary
(non-trachoma-related) antigen exposure that arises through
infection with urogenital Ct, allowing more accurate estimation of
the SCR for trachoma. The framework presented for assessing
cross-sectional serological samples and its link to measures of TF
prevalence has important implications for trachoma surveillance
in an era of declining prevalence22. Modelling suggested that
transmission had declined in all regions. Validation of this could
be undertaken by comparing these ﬁndings with longitudinal
trachoma surveillance data. We would expect to see estimates of
declining transmission reﬂected by reductions in Ct PCR posi-
tivity and TF prevalence between the two cross-sections. In
populations from which historical data (or multiple cross-sec-
tions) were available for this study (Nepal, The Gambia and
Rombo) we see clear declines in TF and PCR prevalence (where
available) mirroring the serological pattern14,18,23. For future
studies, it will be important to ensure that long-term TF and PCR
data are generated in order to validate sero-surveillance data. In
regions aiming to eliminate trachoma as a public health problem,
there are key opportunities for serological data to contribute to
future decisions on when to stop, or if necessary, when to restart
MDA.
If, as intimated above, we need TF data to help validate ser-
ology, why not just keep examining children for TF instead?
Estimation of the SCR may help overcome some of the limitations
of using TF prevalence for post-validation surveillance, without
requiring larger sample sizes. As transmission intensity declines
within a population, the speciﬁcity of TF for ocular Ct infection
decreases3 and it becomes more costly to train graders to identify
TF24. Moreover, age-speciﬁc TF prevalence patterns can be highly
variable, whilst age-speciﬁc sero-prevalence patterns observed
were much more consistent, with the observed variation in sero-
prevalence reﬂecting historical exposure patterns. We therefore
contend that SCR in 1–9 year olds can provide a consistent
measurement of transmission intensity. Photography (of eyelids,
with later grading of photographs for TF) combined with pho-
tographer training, has also been suggested as a potential sur-
veillance approach that might be more cost effective than training
ﬁeld graders25, but evidence is mounting to suggest that drivers
other than Ct may cause the TF phenotype26. We have modelled
post-elimination serological data under various scenarios. More
surveys are still needed to generate examples of sero-prevalence
proﬁles from populations after elimination as a public health
problem has been achieved, and to assess how sero-prevalence
proﬁles might be modiﬁed by differing incidence of urogenital Ct.
Using our mean estimate of sero-prevalence of 7% when TF <5%,
a sample size of at least 51 sero-negative samples would be needed
to conﬁrm maintenance of elimination as a public health pro-
blem. However, conﬁrming sero-prevalence levels <1% would
require substantially larger sample sizes.
There are several limitations to our study. First, for some study
sites, it was difﬁcult to make statistically valid distinctions
between models that accounted for a secondary (urogenital)
exposure to Ct antigens, and those predicting a ﬁxed change point
in trachoma transmission intensity. This was exempliﬁed by the
Solomon Islands data, where exposure to urogenital infection
likely confounds any estimated tc, (reﬂected in the uncertain tc
estimates). Therefore, when comparing scenarios within each
study site, we used our understanding of the epidemiology and
history of interventions to select the most appropriate scenario.
Second, we used the estimated SRR from Nepal as our ﬁxed SRR
estimate for all other study sites, but the SRR may vary between
populations. Moreover, a population-level estimate of the SRR
may not be appropriate for young children, as they tend to have
lower antibody levels and may sero-revert more quickly than
adults. We may need multiple cross-sectional data sets from
children within the same population to quantify the SRR. We did
not account for secondary exposure to urogenital infection in
Nepal. Fortunately, urogenital Ct has a low prevalence in the
general population there27, an observation borne out by the pre-
MDA serological data, where there was no sharp age-dependent
increase in sero-prevalence that would be consistent with Ct
exposure following sexual debut. Third, different study sites used
different platforms to assess each individual’s antibody response,
and it was consequently not possible to directly compare the
antibody acquisition rates against TF prevalence; this problem
does not arise when comparing results of the sero-catalytic
models. Estimates of the best-performing scenario differed
slightly when comparing the sero-catalytic and antibody acqui-
sition models; however, given the issue of confounding related to
estimating tc and the time at which individuals may be exposed to
urogenital infection, this is not unexpected. Fourth, given the very
high prevalence of urogenital infection in the Solomon Islands28
and high sero-prevalence in young children26 we cannot discount
the possibility that these children may have been born to mothers
with urogenital infection and exposed to Ct in the birth canal. In
Fiji, sero-prevalence did not increase with age, suggesting chil-
dren there might experience constant low-level Ct exposure bal-
ancing the effect of natural sero-reversion; this Ct exposure in
children might, for example, be due to para-trachoma. Con-
temporaneous TF prevalence data were not available for this
study site to help further the interpretation of our ﬁndings29.
Fifth, whilst the number of data points evaluated here is sub-
stantially larger than any previous study, data are still limited.
There was therefore a reasonably high level of uncertainty for the
estimated relationship between SCR and TF prevalence, and
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caution should be exercised in drawing deﬁnitive conclusions.
Lastly, we only considered constant age-speciﬁc forces of infec-
tion, which may not truly reﬂect long-term transmission patterns.
There was not sufﬁcient statistical power to consider more
complex temporal trends.
In order to further understand and provide additional ver-
iﬁcation of the ﬁndings of this study, we offer several con-
siderations for future work. First, an increase in the number of
sero-surveillance studies conducted within countries that pre-
viously had trachoma as a public health problem are needed. This
would provide greater insight into Pgp3 and CT694 sero-
prevalence at sub-critical levels of trachoma transmission. Sec-
ond, increasing the number of samples collected from individuals
outside of the 1–9 years of age indicator group, with multiple
cross-sections conducted several years apart from one another,
would help to ensure the estimated SRR is correct. Third, in order
to test the predictions currently made by our models, we would
seek to increase the quantity of serological data available from
regions very close to the TF <5% target. From these data we could
explore how much variation there is in SCRs in populations close
to the threshold for TF’s elimination as a public health problem.
It remains challenging to correlate serological ﬁndings and (1)
integrate them with results that have been generated from exist-
ing, more-established data on disease, and (2) use them to inform
re-evaluation of current guidelines30. However, here we have
demonstrated the potential utility of antibody-based surveillance
to help monitor low-levels of ocular Ct infection transmission.
We have initiated an evidence base for the use of sero-surveillance
by programmes in low-transmission and post-elimination set-
tings (where TF <5%), and have provided an operational
threshold for sero-surveillance. Across a number of infectious
diseases there is now a concerted effort towards integrated sero-
surveillance, where samples from the same cross-sectional survey
are tested for antibody responses to multiple pathogens simul-
taneously, using a multiplexed bead-based immunoassay
platform31,32. Given the enormous potential of integrated sur-
veillance afforded by multiplexing, it is likely that an increasing
amount of data of the format analysed here will become available
in the future. This will increase the need for appropriate analytic
methods. The approaches applied here could be adopted for other
diseases, to help generate understanding of low-transmission
scenarios, determine how such data can complement existing
programme evaluation methods and guide future study design in
the post-MDA phase.
Methods
Data. We used the data on antibody responses and TF collected from trachoma-
endemic populations of Fiji (two different ethnic populations), Kiribati, Nepal,
Solomon Islands, The Gambia, and the United Republic of Tanzania (Rombo dis-
trict). A map which highlights the countries from which data were available is pre-
sented in the Supplementary Information (Supplementary Figure 2). Full details of the
ﬁeld and laboratory methodologies, relevant ethical and regulatory board approval are
provided elsewhere14,16,33–35. A summary of the demography of each population is
provided in Supplementary Table 1, and age-speciﬁc prevalence curves for TF and
sero-positivity to Ct antigens are presented in Fig. 1. Data on antibody response
against Pgp3 and CT694 were available for Nepal and Rombo, whilst serological data
from all other sites were limited to Pgp3. Thresholds to determine sero-positivity were
deﬁned for each dataset separately. Data generated using multiplex bead array (Nepal
and Rombo), were provided as median ﬂuorescence intensity (MFI) with background
subtracted out (MFI-BG), with threshold cut-offs determined using a receiver oper-
ating characteristic (ROC) curve, based on previously-assayed dried blood spots from
children in a trachoma-endemic district of Tanzania (Kongwa district)7. Thresholds
for the data collected as optical density (OD) values were deﬁned as the mean plus
three SDs of the OD in sero-negative controls36.
Ethics. As a secondary analysis of pre-existing data sets, this study was considered
by the Research Ethics Review Committee of the World Health Organization to be
exempt from full review (0003001).
Modelling and model ﬁtting. To investigate age and exposure-dependent changes
in anti-Pgp3 and anti-CT694 antibody responses, data were analysed using two dis-
tinct statistical models: (i) sero-catalytic models to describe how the proportion of
sero-positive individuals changes with age, dependent on historical exposure to Ct8,9;
and (ii) antibody acquisition models to describe how geometric mean antibody levels
change with age and exposure17. Age-dependent variation in sero-prevalence or
antibody levels can be used to infer historical patterns of trachoma transmission. For
both sero-catalytic and antibody acquisition models, three distinct transmission sce-
narios were considered: scenario 1 assumed a constant rate of transmission; scenario 2
assumed a sharp drop in transmission tc years ago; and scenario 3 assumed a linear
decline in transmission8,17. Assumptions and parameters estimated from the data for
each scenario are presented in Table 1. Full mathematical descriptions of the models
are provided in the Supplementary Methods.
A key challenge when modelling serological data is parameter identiﬁability,
where the data may not provide sufﬁcient statistical power to allow precise
parameter estimation. An important example occurs when estimating SCRs (λ) and
SRRs (ρ). If the data are limited, it is not always possible to distinguish between the
case where antibodies are acquired rapidly and then decay rapidly, and the case
where antibodies are acquired slowly and decay slowly37. However, the cohorts in
this study were considered of sufﬁcient size to allow estimation of sero-catalytic
model parameters37. We tested variants of each model while ﬁxing the SRR with
the estimate from Nepal. Antibodies to Pgp3 and CT694 are also generated during
urogenital Ct infection, therefore, we accounted for a second potential source of
antigen exposure following sexual debut at age 18 years28. We ﬁtted up to 10
different sero-catalytic models to each dataset for which the data on the whole
population were available, and six different models where information on
individuals <16 years of age were available. For both the sero-catalytic and antibody
acquisition models, inference was implemented at population level, and we
therefore consider sero-conversion, reversion and antibody acquisition and decay
at population level.
Parameter estimation was performed using Markov Chain Monte Carlo, and chain
convergence was assessed by ensuring a Gelman-Rubin statistic <1.138 and effective
sample size >350. Model comparison statistics were calculated using the DIC39.
Although historical exposure to trachoma can determine age-stratiﬁed sero-prevalence
curves, serological data from a single cross-sectional study are often insufﬁcient to
statistically distinguish between competing explanations for changes in transmission
intensity. If several scenarios provided comparable descriptions of the data (as judged by
DIC), we selected the scenario that best ﬁtted with prior epidemiological knowledge of
that setting, e.g. the occurrence of an intervention program, or the transmission of
urogenital Chlamydia. Additional details on the modelling methodology, ﬁtting and
convergence diagnostics are provided in the Supplementary Methods. All calculations
and analysis were performed using R version 3.3.140.
We compared results from the sero-prevalence models across all sites. However,
due to the use of different antibody assays in different sites, results from antibody
acquisition models could not be compared between sites. To understand the
relationship between different measures of transmission intensity (SCR and TF
prevalence) we ﬁtted a linear model to the relationship between λT (for Pgp3) and
TF prevalence for each study site. We ﬁtted λT as a function of TF prevalence, and
predicted the relationship between TF prevalence and λT.
Code availability. All code is available on GitHub: https://github.com/Pinzo1/
Serology_code-.
Data availability
All data analysed in this study are previously published. The authors declare that all
other data supporting the ﬁndings of this study are available within https://github.
com/Pinzo1/Serology_code-, or are available from the authors upon request.
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